Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the diagnosis and management of acute severe ulcerative colitis.

IF 2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY
Ingrid Ordás, Berta Caballol, Antonio Giordano, Maria Esteve, Francisco Rodríguez-Moranta, Raquel Bravo, Joan Trabal, Xavier Segú, Luís Menchén, Ana Gutiérrez-Casbas, Yamile Zabana
{"title":"Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the diagnosis and management of acute severe ulcerative colitis.","authors":"Ingrid Ordás, Berta Caballol, Antonio Giordano, Maria Esteve, Francisco Rodríguez-Moranta, Raquel Bravo, Joan Trabal, Xavier Segú, Luís Menchén, Ana Gutiérrez-Casbas, Yamile Zabana","doi":"10.1016/j.gastrohep.2026.502815","DOIUrl":null,"url":null,"abstract":"<p><p>Acute severe ulcerative colitis (ASUC) is a potentially life-threatening medical emergency that requires hospitalization, close multidisciplinary monitoring, and prompt, protocolized decision-making. Despite therapeutic advances, ASUC remains associated with high morbidity and mortality, substantial healthcare resource utilization, and a significant risk of colectomy. This position statement from the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) provides updated, evidence-based recommendations for the diagnosis and management of ASUC in clinical practice. Its development involved a comprehensive review of the literature, including clinical trials, observational studies, and the most recent international guidelines. Diagnosis must be rapid and standardized, with particular emphasis on the systematic exclusion of infections, especially Clostridioides difficile and cytomegalovirus. Intravenous corticosteroids remain the first-line treatment, and response should be assessed at 72hours using validated criteria. In steroid-refractory patients, infliximab and cyclosporine are equally effective rescue therapies, and the choice between them should be individualized according to patient characteristics and comorbidities. JAK inhibitors are emerging as a promising option in selected cases, although current evidence is still limited. Supportive measures, including optimization of nutritional status, thromboprophylaxis, and continuous close monitoring, constitute essential components of care. Early surgical assessment is also crucial in patients who fail to respond to medical therapy or who develop complications. The management of ASUC requires a structured, interdisciplinary approach delivered in specialized centers, integrating early diagnosis, optimization of medical therapy, and timely surgical decision-making. This consensus aims to harmonize clinical practice and contribute to improving outcomes in patients with ASUC.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502815"},"PeriodicalIF":2.0000,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologia y hepatologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gastrohep.2026.502815","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening medical emergency that requires hospitalization, close multidisciplinary monitoring, and prompt, protocolized decision-making. Despite therapeutic advances, ASUC remains associated with high morbidity and mortality, substantial healthcare resource utilization, and a significant risk of colectomy. This position statement from the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) provides updated, evidence-based recommendations for the diagnosis and management of ASUC in clinical practice. Its development involved a comprehensive review of the literature, including clinical trials, observational studies, and the most recent international guidelines. Diagnosis must be rapid and standardized, with particular emphasis on the systematic exclusion of infections, especially Clostridioides difficile and cytomegalovirus. Intravenous corticosteroids remain the first-line treatment, and response should be assessed at 72hours using validated criteria. In steroid-refractory patients, infliximab and cyclosporine are equally effective rescue therapies, and the choice between them should be individualized according to patient characteristics and comorbidities. JAK inhibitors are emerging as a promising option in selected cases, although current evidence is still limited. Supportive measures, including optimization of nutritional status, thromboprophylaxis, and continuous close monitoring, constitute essential components of care. Early surgical assessment is also crucial in patients who fail to respond to medical therapy or who develop complications. The management of ASUC requires a structured, interdisciplinary approach delivered in specialized centers, integrating early diagnosis, optimization of medical therapy, and timely surgical decision-making. This consensus aims to harmonize clinical practice and contribute to improving outcomes in patients with ASUC.

西班牙克罗恩病和溃疡性结肠炎(geteccu)工作组关于急性严重溃疡性结肠炎诊断和管理的立场声明。
急性严重溃疡性结肠炎(ASUC)是一种可能危及生命的医疗紧急情况,需要住院治疗、密切的多学科监测和及时的、有协议的决策。尽管治疗取得了进展,但ASUC仍然与高发病率和死亡率、大量医疗资源占用和结肠切除术的重大风险相关。西班牙克罗恩病和溃疡性结肠炎工作组(GETECCU)的立场声明为临床实践中ASUC的诊断和管理提供了最新的循证建议。它的发展涉及对文献的全面回顾,包括临床试验、观察性研究和最新的国际指南。诊断必须快速和标准化,特别强调系统地排除感染,特别是艰难梭状芽胞杆菌和巨细胞病毒。静脉注射皮质类固醇仍然是一线治疗,应在72小时后使用有效的标准评估疗效。在类固醇难治性患者中,英夫利昔单抗和环孢素是同样有效的抢救治疗,两者之间的选择应根据患者特点和合并症进行个体化。尽管目前的证据仍然有限,但在某些病例中,JAK抑制剂正成为一种有希望的选择。支持性措施,包括优化营养状况、血栓预防和持续密切监测,是护理的基本组成部分。对于药物治疗无效或出现并发症的患者,早期手术评估也至关重要。结论:ASUC的治疗需要在专业中心采用结构化的、跨学科的方法,整合早期诊断、优化药物治疗和及时的手术决策。这一共识旨在协调临床实践,并有助于改善ASUC患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gastroenterologia y hepatologia
Gastroenterologia y hepatologia GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
1.50
自引率
10.50%
发文量
147
审稿时长
48 days
期刊介绍: Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书